CPA Healthworld Adds Zeneca, Serono and Almirall Prodesfarma Accounts.

NEW YORK--(BUSINESS WIRE)--Jan. 6, 1999--Healthworld Corporation (NASDAQ: HWLD) today announced that CPA Healthworld has won three new accounts.

The wins, according to the Madrid agency's CEO Enrique Alda, include Zeneca's Accolate, a new leukotriene inhibitor indicated for the treatment of asthma, Serono's Gonal F hormone for infertility and Almirall Prodesfarma's Airtal, Spain's leading anti-inflammatory drug.

Established in 1992, CPA Espana was acquired by Healthworld Corporation in October, 1998. One of the most successful and fastest growing agencies in Spain, CPA Healthworld provides a wide range of communication services to the Spanish healthcare market, including advertising, public relations, sales support materials, design and exhibitions. Steven Girgenti, Chairman and Chief Executive Officer of Healthworld, stated, "We are delighted with the accelerating growth of CPA Healthworld, as demonstrated by the addition of these important new accounts."

Healthworld is an international marketing and communications services company specializing in healthcare. The company provides many of the world's largest pharmaceutical and other healthcare companies with a comprehensive range of integrated strategic marketing services designed to accelerate the market acceptance of new products and to sustain marketability throughout their life cycles, including advertising and promotion, contract sales, consulting, publishing, medical education, public relations, interactive multimedia, database marketing and marketing research services.

This press release contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management team. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, competitive, economic and regulatory factors in the health care marketing and communications industry and the pharmaceutical and health care industry, general economic conditions, the ability of Healthworld to manage its growth and successfully implement its business strategy and other risks and uncertainties that may be detailed, from time to time, in Healthworld's reports filed with the Securities and Exchange Commission.